{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:21:58Z","timestamp":1759335718671,"version":"3.37.3"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"Supplement_B","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The ISCHEMIA trial found no statistical difference in the primary endpoint between initial invasive and conservative management of patients with chronic coronary disease and moderate-to-severe ischaemia on stress testing. However, an invasive strategy increased peri-procedural myocardial infarction (MI) but decreased spontaneous MI with continued separation of curves over time. Thus, in order to assess the long-term effect of invasive management strategy on mortality, the ISCHEMIA-EXTEND observational study was planned including surviving participants from the initial phase of the ISCHEMIA trial with a projected median follow-up of nearly 10 years. Recently, an interim report of 7-year all-cause, cardiovascular (CV), and non-CV mortality rates has been published showing no difference in all-cause mortality between the two strategies, but with a lower risk of CV mortality and higher risk of non-CV mortality with an initial invasive strategy over a median follow-up of 5.7 years. The trade-offs in CV and non-CV mortality observed in ISCHEMIA-EXTEND raise many important questions regarding the heterogeneity of treatment effect, the drivers of mortality, and the relative importance and reliability of CV vs. all-cause mortality. Overall, findings from ISCHEMIA and ISCHEMIA-EXTEND trials might help physicians in shared decision-making as to whether to add invasive management to guideline-directed medical management in selected patients with chronic coronary artery disease and moderate or severe ischaemia.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad064","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:58:49Z","timestamp":1682099929000},"page":"B34-B36","source":"Crossref","is-referenced-by-count":6,"title":["Long-term follow-up after invasive or conservative management of stable coronary disease: the ISCHEMIA-EXTEND study"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-7870","authenticated-orcid":false,"given":"Leonardo","family":"Bolognese","sequence":"first","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedaliera Toscana Sudest , Arezzo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Rocco","family":"Reccia","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedaliera Toscana Sudest , Arezzo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sabini","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedaliera Toscana Sudest , Arezzo , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"2023042117451919900_suad064-B1","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"key":"2023042117451919900_suad064-B2","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"2023042117451919900_suad064-B3","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"BARI 2D Study Group","year":"2009","journal-title":"N Engl J Med"},{"key":"2023042117451919900_suad064-B4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1408758","article-title":"Fractional flow reserve\u2013guided PCI for stable coronary artery disease","volume":"371","author":"De Bruyne","year":"2014","journal-title":"N Engl J Med"},{"key":"2023042117451919900_suad064-B5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/CIRCULATIONAHA.120.047987","article-title":"Myocardial infarction in the ISCHEMIA trial: impact of different definitions on incidence, prognosis, and treatment comparisons","volume":"143","author":"Chaitman","year":"2021","journal-title":"Circulation"},{"key":"2023042117451919900_suad064-B6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2022.01.017","article-title":"Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial","volume":"248","author":"Sidhu","year":"2022","journal-title":"Am Heart J"},{"key":"2023042117451919900_suad064-B7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ahj.2013.09.008","article-title":"Prognostic implications of procedural vs spontaneous myocardial infarction: results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry","volume":"166","author":"Bangalore","year":"2013","journal-title":"Am Heart J"},{"key":"2023042117451919900_suad064-B8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.122.062714","article-title":"Survival after invasive or conservative management of stable coronary disease","volume":"147","author":"Hochman","year":"2023","journal-title":"Circulation"},{"key":"2023042117451919900_suad064-B9","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1093\/eurheartj\/ehab246","article-title":"Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis","volume":"42","author":"Navarese","year":"2021","journal-title":"Eur Heart J"},{"key":"2023042117451919900_suad064-B10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/CIRCULATIONAHA.120.049755","article-title":"Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity","volume":"144","author":"Reynolds","year":"2021","journal-title":"Circulation"},{"key":"2023042117451919900_suad064-B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/caac.21132","article-title":"Cancer risks associated with external radiation from diagnostic imaging procedures","volume":"62","author":"Linet","year":"2012","journal-title":"Cancer J Clin"},{"key":"2023042117451919900_suad064-B12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","article-title":"Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis","volume":"65","author":"Palmerini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023042117451919900_suad064-B13","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"2023042117451919900_suad064-B14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0735-1097(99)00250-8","article-title":"Cause of death in clinical research: time for a reassessment?","volume":"34","author":"Lauer","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2023042117451919900_suad064-B15","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jacc.2020.07.002","article-title":"Limitations of long-term mortality as a clinical trial endpoint: time wounds all healing","volume":"76","author":"Seto","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023042117451919900_suad064-B16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B34\/50060998\/suad064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_B\/B34\/50060998\/suad064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:58:57Z","timestamp":1682099937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_B\/B34\/7135757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":16,"journal-issue":{"issue":"Supplement_B","published-online":{"date-parts":[[2023,4,21]]},"published-print":{"date-parts":[[2023,4,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad064","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"type":"print","value":"1520-765X"},{"type":"electronic","value":"1554-2815"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,4,1]]}}}